Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IFRX Stock Forecast 2026-2027
$1.84
Current Price
$271.02M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to IFRX Price Targets
+645.1%
To High Target of $13.71
+379.0%
To Median Target of $8.81
+59.9%
To Low Target of $2.94
IFRX Price Momentum
-23.3%
1 Week Change
-26.4%
1 Month Change
+121.7%
1 Year Change
+82.2%
Year-to-Date Change
-37.6%
From 52W High of $2.95
+148.3%
From 52W Low of $0.74
📊 TOP ANALYST CALLS
Did IFRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if InflaRx is one of their latest high-conviction picks.
Latest IFRX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, IFRX has a bullish consensus with a median price target of $8.81 (ranging from $2.94 to $13.71). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $1.84, the median forecast implies a 379.0% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IFRX Analyst Ratings
6
Buy
1
Hold
0
Sell
IFRX Price Target Range
Low
$2.94
Average
$8.81
High
$13.71
Current: $1.84
Latest IFRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IFRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2026 | Raymond James | Ryan Deschner | Strong Buy | Upgrade | $9.00 |
| May 11, 2026 | HC Wainwright & Co. | Matthew Keller | Buy | Maintains | $8.00 |
| May 11, 2026 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Maintains | $4.00 |
| Apr 21, 2026 | Guggenheim | Buy | Reiterates | $N/A | |
| Mar 20, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Dec 30, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 3, 2025 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Nov 10, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Sep 2, 2025 | HC Wainwright & Co. | Matthew Keller | Buy | Assumes | $6.00 |
| May 29, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 8, 2025 | Oppenheimer | Outperform | Initiates | $N/A | |
| Apr 29, 2025 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Mar 26, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 7, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 16, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 20, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
InflaRx N.V. (IFRX) Competitors
The following stocks are similar to InflaRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InflaRx N.V. (IFRX) Financial Data
InflaRx N.V. has a market capitalization of $271.02M with a P/E ratio of -2.7x. The company generates $33,801 in trailing twelve-month revenue with a -24,677.9% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -144,769.8% and return on equity of -79.9%.
Valuation Metrics
Market Cap
$271.02M
Enterprise Value
$108.37M
P/E Ratio
-2.7x
PEG Ratio
0.1x
Price/Sales
9,240.0x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-144,769.8%
Net Margin
-24,677.9%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+29.9%
Current Ratio
4.2x
Debt/Equity
2.2x
ROE
-79.9%
ROA
-39.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
InflaRx N.V. (IFRX) Business Model
About InflaRx N.V.
What They Do
Develops innovative anti-inflammatory therapeutics.
Business Model
InflaRx N.V. operates as a clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative therapies targeting the complement system's C5a pathway. The company generates revenue primarily through partnerships, grants, and potential product sales from its lead program and pipeline candidates aimed at treating various inflammatory diseases.
Additional Information
Founded in 2007 and headquartered in Jena, Germany, InflaRx is dedicated to discovering first-in-class or best-in-class inhibitors for life-threatening inflammatory conditions. Its lead product, vilobelimab, is designed to block inflammatory mediators while preserving essential immune functions, and the pipeline includes treatments for severe conditions such as COVID-19 and certain cancers.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
74
CEO
Dr. Niels C. Riedemann M.D., Ph.D.
Country
Germany
IPO Year
2017
Website
www.inflarx.deInflaRx N.V. (IFRX) Latest News & Analysis
Latest News
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
29 days ago
Quick Summary
InflaRx (NASDAQ: IFRX) will focus on developing izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis and other renal diseases, according to CEO Niels Riedemann.
Why It Matters
InflaRx's focus on izicopan for treating ANCA-associated vasculitis could enhance its market position and attract investment, signaling potential for growth in the renal disease treatment sector.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
InflaRx N.V. (IFRX) is focusing on its drug Izicopan for treating ANCA-associated vasculitis and renal diseases, indicating a strategic emphasis on this therapeutic area.
Why It Matters
InflaRx's strategic focus on Izicopan for treating ANCA-associated vasculitis and renal diseases signals potential growth opportunities, impacting future revenue and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
1 month ago
Quick Summary
InflaRx N.V. (Nasdaq: IFRX) plans to develop izicopan, an oral C5a receptor inhibitor, for treating AAV, a severe kidney disorder, and is in Phase 2 planning to expedite its market entry.
Why It Matters
InflaRx's development of izicopan for AAV could position it as a market leader in a niche segment, potentially driving stock value and investor interest amid evolving regulatory dynamics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InflaRx N.V. has priced its underwritten offering of 75 million ordinary shares at $2.00 each, aiming to raise capital for its anti-inflammatory therapeutics.
Why It Matters
InflaRx's $150 million share offering dilutes existing shares, impacting stock value and signaling capital needs, which could influence investor confidence and future growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InflaRx N.V. has completed an underwritten offering of 75 million ordinary shares at $2.00 each, raising $150 million in gross proceeds.
Why It Matters
InflaRx's successful $150 million share offering enhances its financial position, providing capital for R&D, which could drive growth and impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
1 month ago
Quick Summary
InflaRx N.V. reported new pre-clinical data showing low reactive metabolite formation of izicopan, indicating potential safety benefits in drug development.
Why It Matters
New pre-clinical data on izicopan's low reactive metabolite formation suggests reduced safety risks, potentially enhancing its marketability and investor confidence in InflaRx's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IFRX Stock
What is InflaRx N.V.'s (IFRX) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, InflaRx N.V. (IFRX) has a median price target of $8.81. The highest price target is $13.71 and the lowest is $2.94.
Is IFRX stock a good investment in 2026?
According to current analyst ratings, IFRX has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IFRX stock?
Wall Street analysts predict IFRX stock could reach $8.81 in the next 12 months. This represents a 379.0% increase from the current price of $1.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is InflaRx N.V.'s business model?
InflaRx N.V. operates as a clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative therapies targeting the complement system's C5a pathway. The company generates revenue primarily through partnerships, grants, and potential product sales from its lead program and pipeline candidates aimed at treating various inflammatory diseases.
What is the highest forecasted price for IFRX InflaRx N.V.?
The highest price target for IFRX is $13.71 from at , which represents a 645.1% increase from the current price of $1.84.
What is the lowest forecasted price for IFRX InflaRx N.V.?
The lowest price target for IFRX is $2.94 from at , which represents a 59.9% increase from the current price of $1.84.
What is the overall IFRX consensus from analysts for InflaRx N.V.?
The overall analyst consensus for IFRX is bullish. Out of 4 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $8.81.
How accurate are IFRX stock price projections?
Stock price projections, including those for InflaRx N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 8:40 PM UTC